iQ-007 Preclinical Stage Complete — Phase 1 Preparations Targeted for Q1 2025

Princeton, NJ, October 8, 2024 ─ iQure Pharma Inc. (iQure), a US-based global biotech company dedicated to the development of new epilepsy and pain management therapeutics, is proud to announce that its lead asset iQ-007, has completed GLP Tox in rodents. Non-rodent GLP Tox successfully completed its treatment phase and preparations for Phase 1 are in an advanced stage.

iQ-007 is a positive allosteric modulator of the EAAT2 transporter and represents a novel approach to treat neurodegenerative diseases. 

In the last 5 months, the company progressed with its pivotal GLP Tox studies and initiated preparations for Phase 1, scheduled to start in Q1 2025. As of late September, the GLP Tox studies in rodents are complete and initial data analysis is highly encouraging with a very favorable iQ-007 safety profile. In addition, the GLP Tox studies conducted in the second species of dogs, is progressing successfully with positive results from the DRF study and a positive continuation of the 4-week GLP Tox study.

“This excellent set of results allows iQure to move forward swiftly into the clinic phase and investigate the tolerability and pharmacokinetics of iQ-007 in male and female participants. This is a major step forward towards the clinical development of iQ-007 in epilepsy patients and demonstrates the potential for iQ-007 to reduce seizures and improve the quality of life for these patients. We look forward to the first entry into human of iQ-007 early next year.” said Pawel Zolnierczyk, CEO.

About iQure Pharma

iQure Pharma, a global biotech firm headquartered in the US, is focused on the development of new therapeutics for CNS, including neuropathic pain, epilepsy and other neurodegenerative diseases. iQure researchers, clinicians, and pharmaceutical professionals work closely with academic partners, industry experts, and patient organizations to build medically and socially beneficial therapies.

For more information about supporting iQure’s initiatives, contact iQure CEO Pawel Zolnierczyk at pawel.zolnierczyk@iqurepharma.com.

iQ-007 Zebrafish Screening Reveals Positive Results in Other Neurodegenerative Diseases

Princeton, NJ, June 21 2024 ─ iQure Pharma Inc. (iQure), a US-based global biotech  company dedicated to the development of new epilepsy and pain management therapeutics, is proud to announce that its lead asset iQ-007, has shown positive results in a zebrafish screening for a series of neurodegenerative diseases.

iQ-007 is a positive allosteric modulator of the EAAT2 transporter and represents a novel approach to treat neurodegenerative diseases.  Based on the positive results of iQ-007 for epilepsy and the successful completion of the ETSP program, iQure decided to explore the general mechanism of action of iQ-007 in other neurodegenerative diseases. Over the last few months, iQ-007 was tested in a series of in vivo zebrafish models of many high medical need neurodegenerative conditions, including Alzheimer’s disease and Parkinson’s disease. iQ-007 produced statistically significant effects in all models, matching, or in some cases exceeding positive control results, underpinning the importance of the role of EAAT2 in neurodegenerative diseases. “This excellent set of results supports iQ-007 as a Platform Therapeutic with the potential for helping patients who are suffering from these debilitating diseases.” said Pawel Zolnierczyk, iQure CEO. “We are looking forward to continuing to explore iQ-007’s clinical development potential and optimum market positioning.”

About iQure Pharma

iQure Pharma, a global biotech firm headquartered in the US, is focused on the development of new therapeutics for CNS, including neuropathic pain, epilepsy and other neurodegenerative diseases. iQure researchers, clinicians, and pharmaceutical professionals work closely with academic partners, industry experts, and patient organizations to build medically and socially beneficial therapies.

For more information about supporting iQure’s initiatives, contact iQure CEO Pawel Zolnierczyk at pawel.zolnierczyk@iqurepharma.com.

Initial iQ-007 IND-Enabling Tox Results Accelerate Prep for First in Human Phase 1 Study

Princeton, NJ, March 19, 2024 ─ iQure Pharma Inc. (iQure), a US-based global biotech, announced that its asset, iQ-007, a novel anticonvulsant compound, has completed the first stage of pivotal IND-enabling Tox studies in rodent and non-rodent species.

“The recent results confirm what we already know about this exciting compound,” said Pawel Zolnierczyk, CEO. “We’re one step closer to bringing this effective therapeutic to a clinic trial, with the potential to significantly improve patients’ quality of life. Results of recent toxicological studies show that iQ-007 unique mechanism of action as a Positive Allosteric Modulator (PAM) of the EAAT2 neurotransporter, is a very promising therapeutic strategy, ‘triggering a human natural safety mechanism’ that allows for more efficient clearance of excess glutamate which in turn prevents neurotoxicity and seizures.”

iQ-007 is well tolerated and continues to demonstrate an impressive safety profile. iQure Pharma is looking forward to completing the IND-enabling tox study series, which will accelerate the preparation of the First in Human Phase 1 study.

About iQure Pharma:

iQure Pharma, a global biotech firm headquartered in the US, is focused on the development of new therapeutics for CNS, including neuropathic pain, epilepsy and other neurodegenerative diseases. iQure researchers, clinicians, and pharmaceutical professionals work closely with academic partners, industry experts, and patient organizations to build medically and socially beneficial therapies based on a revolutionary glutamate-clearance platform for treating neurodegenerative conditions including neuro-inflammation.

For more information, please contact pawel.zolnierczyk@iqurepharma.com.